A landmark acquisition poised to redefine the future of orthotic and prosthetic care has been announced, as Hanger Inc., a preeminent provider of O&P patient care services and solutions, has completed its acquisition of Liberating Technologies Inc. (LTI). This strategic move significantly bolsters Hanger’s research and innovation capabilities, aiming to accelerate the development and deployment of cutting-edge prosthetic technologies that promise to profoundly improve patient outcomes globally.
Main Facts
Austin, TX – [Insert Date of Publication] – Hanger Inc., a leader in orthotic and prosthetic (O&P) patient care services and solutions, has officially announced the acquisition of Liberating Technologies Inc. (LTI). LTI, a distinguished research organization founded in 2000 and previously under the ownership of Coapt, brings a formidable legacy of pioneering research and development in the O&P field. This acquisition is a critical step in Hanger’s overarching strategy to expand its research and innovation ecosystem, particularly within its Hanger Ventures and Hanger Institute for Clinical Research and Education divisions.
Since its inception, and notably since 2008, LTI has carved out a unique niche through its specialized research team, consistently securing numerous government-funded grants. These grants have propelled the organization to pursue high-impact concepts and develop next-generation technologies that address some of the most pressing challenges faced by O&P patients. The integration of LTI’s expertise is expected to significantly enhance Hanger’s capacity for evidence-based care, fostering advancements that directly translate into improved quality of life for individuals relying on prosthetic and orthotic devices.
The acquisition also marks the complete integration of the Coapt portfolio into the Hanger family, following Hanger’s previously announced intent to acquire Coapt itself. This strategic consolidation underscores Hanger’s commitment to assembling a comprehensive suite of innovative solutions, from advanced myoelectric control systems to groundbreaking research initiatives, all aimed at delivering superior patient care.
A Strategic Alignment: Deepening Hanger’s Innovation Ecosystem
This acquisition is more than just a corporate transaction; it represents a strategic alignment designed to foster unparalleled innovation within the O&P sector. By bringing LTI’s specialized research capabilities under its wing, Hanger is poised to amplify its efforts in advancing clinical practice and ensuring that patient care is continuously informed by the latest scientific discoveries.
The Acquirer: Hanger Inc.’s Legacy and Vision
Hanger Inc. stands as a titan in the orthotic and prosthetic industry, boasting a rich history that spans over 160 years. Founded by James Edward Hanger, who lost a leg during the American Civil War and then developed the first articulated prosthetic foot, the company has consistently been at the forefront of O&P innovation. Today, Hanger operates a vast network of patient care clinics across the United States, providing comprehensive O&P services, and is a major player in product development and distribution.
Hanger’s long-standing mission revolves around empowering human potential through orthotic and prosthetic solutions. Its commitment extends beyond direct patient care to encompass robust investments in research, education, and technological advancement. The company’s strategic vision involves not only delivering high-quality, personalized care but also actively shaping the future of the O&P industry through pioneering research and development. The acquisition of LTI perfectly aligns with this vision, providing a dedicated pipeline for exploring and realizing truly transformative technologies. This dedication is further exemplified by its Hanger Institute for Clinical Research and Education, which serves as a nexus for scientific inquiry, professional development, and the dissemination of best practices.
The Acquired: Liberating Technologies Inc.’s Pioneering Research
Liberating Technologies Inc. (LTI) has, since its establishment in 2000, cultivated a reputation as a crucible for groundbreaking research. With a particular focus since 2008 on securing government-funded grants, LTI has consistently pushed the boundaries of what is possible in prosthetic technology. Their expertise lies in translating complex scientific concepts into tangible solutions that directly address functional limitations and enhance user experience.
LTI’s research portfolio is diverse and impactful, encompassing critical areas such such as:
- Voice-recognition technology for improved prosthesis control: This research aims to offer intuitive, hands-free control mechanisms, significantly enhancing the naturalness and efficiency of prosthetic use.
- Socket cooling systems for residual limb skin health: A common challenge for prosthesis users is skin irritation and breakdown due to heat and moisture. LTI’s work in this area promises to improve comfort, hygiene, and the long-term health of the residual limb.
- Optimizing electrode configurations for pattern recognition control: Pattern recognition control is a sophisticated method that interprets muscle signals to provide more intuitive and precise prosthetic movement. LTI’s research in this field is vital for achieving optimal functional outcomes and a more seamless integration of the prosthesis with the user’s intent.
These initiatives are not merely academic exercises; they represent vital advancements that directly address the daily challenges faced by millions of prosthesis users worldwide. LTI’s proven track record in securing and executing high-value research grants underscores its capacity for innovation and its alignment with national priorities in healthcare technology.
Completing the Coapt Integration
A significant aspect of this acquisition is its role in completing the integration of the Coapt portfolio into Hanger. Hanger had previously announced its impending acquisition of Coapt, a company renowned for its advanced myoelectric pattern recognition control systems that enable more intuitive and functional control of upper-limb prostheses. LTI, having been previously owned by Coapt, represents the research arm that fuels such innovations.
By bringing LTI fully into the Hanger fold, Hanger is not just acquiring a research entity but solidifying its control over the entire innovation lifecycle, from fundamental research and conceptualization (LTI) to advanced product development and commercialization (Coapt’s existing technologies and future innovations). This holistic approach ensures that research findings can be more rapidly translated into clinical applications, offering a distinct competitive advantage and, more importantly, a faster path to patient benefit.
Chronology of Innovation and Integration
Understanding the timeline of these strategic moves provides crucial context for the significance of Hanger’s latest acquisition. It reveals a deliberate and sustained effort by Hanger to solidify its position as an innovation leader in the O&P space.
LTI’s Journey: From Foundation to Acquisition
Liberating Technologies Inc. was founded in the year 2000, emerging from a period of increasing recognition of the need for advanced research in assistive technologies. While its foundational years likely involved establishing its initial research agenda and securing early-stage funding, it was from 2008 onwards that LTI truly hit its stride in government-funded research. This period saw LTI focusing its efforts on securing grants from various federal agencies, including potentially the National Institutes of Health (NIH), the Department of Defense (DoD) – given the focus on prosthetics for veterans – and other relevant bodies that support medical and rehabilitation technology.
Over the years, LTI’s consistent success in grant acquisition allowed it to build a specialized team of engineers, scientists, and clinicians dedicated to pushing the envelope in prosthetic design and control. Their work, often operating at the intersection of biomechanics, neuroscience, and materials science, positioned them as a valuable asset, eventually attracting the attention of Coapt, a company focused on bringing advanced myoelectric control systems to market. Coapt’s acquisition of LTI (prior to Hanger’s involvement) was a logical step to secure a dedicated research engine for its product development.
Hanger’s Strategic Acquisitions: A Pattern of Growth
Hanger Inc.’s acquisition of LTI is not an isolated event but rather a continuation of a well-defined strategy of growth through both organic development and strategic acquisitions. The company has a history of integrating innovative technologies and services to enhance its offerings and market presence.
The announcement of Hanger’s impending acquisition of Coapt in 2025 (assuming this is a recent event despite the future year given in the original text, interpreted as ‘recently completed’) was a clear signal of Hanger’s intent to dominate the advanced prosthetic control segment. Coapt’s leadership in pattern recognition technology for upper-limb prostheses was a crucial addition, allowing Hanger to offer more intuitive and functional solutions directly to its patient base. The subsequent acquisition of LTI, Coapt’s research arm, completes this strategic maneuver. It ensures that Hanger not only gains access to Coapt’s existing commercialized technologies but also secures the intellectual property, talent, and ongoing research pipeline that will drive the next generation of innovations building upon Coapt’s foundation. This sequential integration demonstrates a meticulous approach to consolidating key players and capabilities within the O&P innovation ecosystem.
Supporting Data and Market Context
The acquisition of LTI by Hanger occurs within a dynamic and evolving orthotic and prosthetic market, driven by demographic shifts, technological advancements, and increasing demand for personalized healthcare solutions.
The Expanding Orthotic and Prosthetic Market
The global orthotics and prosthetics market is experiencing significant growth, fueled by several factors. An aging global population contributes to a higher incidence of conditions requiring O&P devices, such as diabetes-related amputations and degenerative musculoskeletal disorders. Furthermore, advancements in medical care have improved survival rates for trauma victims, including military personnel and accident survivors, who often require O&P interventions.
The market is also propelled by increasing awareness of the benefits of O&P devices in improving mobility, independence, and overall quality of life. Patients today expect more than just basic functionality; they seek devices that are lightweight, comfortable, aesthetically pleasing, and highly integrated with their natural body movements. This demand for sophisticated, high-performance solutions creates a fertile ground for companies like Hanger that are willing to invest heavily in research and development. Industry reports often project compound annual growth rates (CAGRs) for this market in the mid-to-high single digits, indicating a robust and expanding sector.
The Imperative for Advanced Research
Within this growing market, the imperative for advanced research is paramount. Traditional prosthetic and orthotic devices, while functional, often fall short in replicating the intricate biomechanics and sensory feedback of natural limbs. The current landscape is characterized by a push towards:
- Neuroprosthetics: Devices that directly interface with the nervous system to provide more intuitive control and sensory feedback.
- Robotics and AI: Integration of robotic components and artificial intelligence for adaptive control, gait analysis, and personalized device optimization.
- Advanced Materials: Development of lighter, stronger, and more biocompatible materials that enhance comfort, durability, and performance.
- Additive Manufacturing (3D Printing): Customization and rapid prototyping of O&P devices, leading to better fit and faster delivery.
- Digital Health Integration: Wearable sensors, telehealth platforms, and data analytics to monitor device performance, patient activity, and facilitate remote adjustments and care.
LTI’s research initiatives, such as voice recognition, socket cooling, and optimized pattern recognition, directly address these cutting-edge areas. By acquiring LTI, Hanger is strategically positioning itself to be at the forefront of these transformative trends, ensuring that its clinical services are backed by the most advanced technologies available.
Government Funding and Research Impact
Government-funded grants play a critical role in advancing medical research, particularly in fields like prosthetics where the initial investment in R&D can be substantial and the path to commercialization lengthy. Agencies such as the National Institutes of Health (NIH), the Department of Defense (DoD), and the Department of Veterans Affairs (VA) are major contributors to O&P research, often driven by the needs of veterans and individuals with disabilities.
LTI’s consistent success in securing these grants is a testament to the scientific merit and potential impact of its research proposals. This external validation, coupled with significant funding, has allowed LTI to pursue ambitious projects that might otherwise be too costly or risky for purely private funding in their early stages. The acquisition means that Hanger now gains direct access to LTI’s expertise in navigating the grant landscape, its existing grant portfolio, and the intellectual property developed through these public investments. This not only provides a financial boost to Hanger’s R&D efforts but also aligns Hanger with national research priorities, potentially opening doors for future collaborations and funding opportunities.
Official Responses and Synergies
The official statements from key leadership figures at Hanger underscore the strategic importance of this acquisition and highlight the anticipated synergies. Their responses paint a picture of a unified vision aimed at accelerating innovation and enhancing patient care.
Leadership Perspectives on the Merger
Pete Stoy, Hanger’s Chief Executive Officer, articulated the company’s rationale with clear foresight: “The addition of LTI strengthens Hanger’s continued commitment to expanding research and development, advancing clinical practice, and improving patient outcomes through evidence-based care.” This statement emphasizes the multi-faceted benefits of the acquisition – not just bolstering R&D, but directly impacting clinical practice and patient well-being. Stoy’s further comment, “This partnership also reflects our ambition to accelerate global technological progress for O&P patients and to join forces with current and future collaborators to drive the next generation of innovation,” reveals a broader aspiration for Hanger to act as a catalyst for industry-wide progress, inviting collaboration to push the boundaries of O&P technology on a global scale. This suggests Hanger sees itself not just as a provider but as a central hub for O&P innovation.
On the acquired side, Todd Farrell, PhD, who now serves as Vice President of Research and Development for Hanger, and previously led LTI, expressed enthusiasm for the integration: “We are excited about this opportunity to become a part of the Hanger ecosystem, which will provide LTI with the technical resources, and the access to clinical insights and clinical data that can help us further drive and enhance innovation.” Dr. Farrell’s comments highlight the crucial resources that Hanger brings to LTI – specifically, technical infrastructure and, perhaps most importantly, direct access to a vast repository of clinical insights and real-world patient data. This direct link between cutting-edge research and clinical application is invaluable, allowing researchers to rapidly test hypotheses, gather feedback, and iterate on designs with unparalleled efficiency.
Synergistic Integration within Hanger Ventures and Hanger Institute
LTI is set to integrate directly into Hanger Ventures and the Hanger Institute for Clinical Research and Education. This is a critical structural decision designed to maximize synergy and accelerate progress. Hanger Ventures is typically focused on identifying and investing in promising technologies and companies, while the Hanger Institute is dedicated to fostering clinical research, education, and evidence-based practices.
By placing LTI within this existing framework, Hanger ensures that LTI’s research initiatives are not siloed but are deeply embedded within a system designed for innovation translation. The LTI team will continue to lead its current grant-funded initiatives, including the development of voice-recognition technology, socket cooling systems, and optimized electrode configurations. However, their integration into Hanger provides them with an expanded platform to actively pursue new research and development opportunities, benefiting from Hanger’s extensive network of clinicians, engineers, and market strategists. This structure fosters a feedback loop where clinical needs inform research priorities, and research findings are rapidly evaluated for clinical applicability.
A Unified Vision for Patient Outcomes
The consistent message from leadership is a unified vision centered on improving patient outcomes. The acquisition is not merely about expanding market share or intellectual property; it is fundamentally about enhancing the lives of individuals who rely on O&P devices. By bringing together Hanger’s clinical expertise and broad patient reach with LTI’s specialized research prowess, the combined entity is uniquely positioned to deliver solutions that are not only technologically advanced but also clinically relevant and patient-centric. The emphasis on "evidence-based care" further reinforces this commitment, ensuring that all innovations undergo rigorous testing and validation before being integrated into clinical practice.
Implications for the Future of O&P Care
The acquisition of Liberating Technologies Inc. by Hanger Inc. carries significant implications, promising to reshape the landscape of orthotic and prosthetic care for years to come. This strategic move is poised to accelerate technological progress, enhance clinical practice, and ultimately deliver unprecedented benefits to patients.
Accelerating Next-Generation Prosthetic Technologies
One of the most profound implications is the accelerated development of next-generation prosthetic technologies. LTI’s expertise in areas like advanced control systems (voice recognition, pattern recognition optimization) and patient comfort solutions (socket cooling) directly addresses critical gaps in current prosthetic offerings. Under Hanger’s expanded resources and clinical insights, these projects are likely to move from research to commercialization with greater speed and efficacy.
Imagine a future where:
- Prostheses respond to verbal commands: Enhancing functionality for users with limited dexterity or those in situations requiring hands-free operation.
- Residual limbs remain cool and comfortable: Significantly reducing skin breakdown, infections, and discomfort, thereby increasing prosthetic wear time and user compliance.
- Intuitive control becomes the norm: Pattern recognition, refined by LTI’s ongoing work, will allow prosthetic users to control their devices with thoughts and muscle movements that feel almost natural, mirroring the dexterity of a biological limb.
- Personalized prosthetics become more widespread: Leveraging Hanger’s vast patient data and LTI’s research, devices could be more precisely tailored to individual biomechanics, lifestyles, and aesthetic preferences.
This synergy promises a paradigm shift from merely functional prosthetics to truly integrated, responsive, and comfortable assistive devices that empower users to live fuller, more active lives.
Enhancing Clinical Practice and Evidence-Based Care
The integration of LTI’s research capabilities into the Hanger Institute for Clinical Research and Education will significantly enhance evidence-based care across Hanger’s extensive network of clinics. The direct feedback loop between researchers and clinicians means that new discoveries can be rapidly translated into best practices, and clinical challenges can directly inform research priorities.
This will lead to:
- Faster adoption of validated technologies: Hanger’s clinicians will be among the first to be trained on and utilize LTI-developed innovations, ensuring that patients receive the most advanced care available.
- Improved patient assessment and device fitting: Research into optimal electrode configurations and user interfaces will lead to more precise and effective prosthetic fittings, maximizing functional outcomes.
- Enhanced professional education: The Hanger Institute will be able to disseminate cutting-edge research findings and clinical protocols to its vast network of O&P professionals, elevating the standard of care across the industry.
- Data-driven decision making: The wealth of clinical data Hanger collects, combined with LTI’s analytical capabilities, will foster a deeper understanding of device performance and patient needs, leading to continuous improvement.
The Broader Impact on Patients and the Industry
Ultimately, the acquisition’s most significant impact will be on the patients. The development of more advanced, comfortable, and intuitive prosthetic technologies will translate into greater independence, improved quality of life, and reduced long-term health complications associated with ill-fitting or suboptimal devices. Patients will benefit from devices that not only restore function but also integrate seamlessly into their daily lives, fostering greater confidence and participation in society.
For the broader O&P industry, this acquisition signals a new era of intensified innovation. As Hanger, now fortified with LTI’s research prowess and the full Coapt portfolio, pushes the boundaries, it will likely inspire other players in the market to increase their investments in R&D, fostering a healthy competitive environment that ultimately benefits patients. Hanger’s ambition to "accelerate global technological progress" suggests a leadership role in driving collaborative research and setting new benchmarks for the entire field. This strategic consolidation of research, development, and clinical expertise positions Hanger Inc. as an undeniable force in shaping the future of orthotic and prosthetic care worldwide.
